ondansetron and tacrine

ondansetron has been researched along with tacrine in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's5 (41.67)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Giacomini, KM; Kido, Y; Matsson, P1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Harder, JA; Kelly, ME1
Del Río, J; Diez-Ariza, M; García-Alloza, M; Lasheras, B; Ramírez, MJ; Redondo, C1
N'Da, CI; Petzer, A; Petzer, JP1
Eriksson, LA; Gholami, A; Minai-Tehrani, D1

Other Studies

12 other study(ies) available for ondansetron and tacrine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
    Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21

    Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship

2003
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
    Journal of medicinal chemistry, 2011, Jul-14, Volume: 54, Issue:13

    Topics: Drug Interactions; HEK293 Cells; High-Throughput Screening Assays; Humans; Kidney; Ligands; Models, Molecular; Molecular Structure; Organic Cation Transport Proteins; Organic Cation Transporter 2; Polymorphism, Genetic; Prescription Drugs; Protein Binding; Small Molecule Libraries; Structure-Activity Relationship

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The effect of several putative cognition enhancers on a water maze acquisition deficit produced by pCPA + scopolamine combination treatment.
    Pharmacology, biochemistry, and behavior, 1997, Volume: 56, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cholinesterase Inhibitors; Cognition; Drug Interactions; Fenclonine; Male; Maze Learning; Muscarinic Agonists; Muscarinic Antagonists; Ondansetron; Oxotremorine; Rats; Scopolamine; Serotonin Agents; Serotonin Antagonists; Tacrine

1997
Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.
    Psychopharmacology, 2003, Volume: 169, Issue:1

    Topics: Animals; Cholinesterase Inhibitors; Drug Therapy, Combination; Flumazenil; Learning; Male; Maze Learning; Memory; Muscarinic Antagonists; Ondansetron; Rats; Rats, Wistar; Receptors, GABA-A; Scopolamine; Serotonin Antagonists; Tacrine

2003
The inhibition of acetylcholinesterase by dantrolene and ondansetron.
    Drug research, 2015, Volume: 65, Issue:1

    Topics: Antiemetics; Cholinesterase Inhibitors; Dantrolene; Erythrocytes; Humans; Inhibitory Concentration 50; Muscle Relaxants, Central; Ondansetron; Ranitidine; Tacrine

2015
In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
    Scientific reports, 2023, 01-12, Volume: 13, Issue:1

    Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Ondansetron; Rivastigmine; Structure-Activity Relationship; Tacrine

2023